COMMUNIQUÉS West-GlobeNewswire

Bavarian Nordic Launches Planned Share Buy-Back Program
07/01/2026
COPENHAGEN, Denmark, January 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the share buy-back program announced on December 2, 2025 , under which the Company intends to repurchase own [...]
Relation Announces Strategic Collaboration with Deerfield Management to Advance Novel Therapeutics
07/01/2026
LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Relation and healthcare investment firm Deerfield Management, a current investor, today announced the establishment of a new research collaboration to advance therapeutic [...]
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
07/01/2026
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform Lehi Utah, Jan. 07, 2026 (GLOBE NEWSWIRE [...]
Correction: JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
07/01/2026
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the program Supports the feasibility of intravenous and subcutaneous dosing regimens in upcoming clinical [...]
Is MEDVi a Trusted GLP-1 Supplier for 2026? What to Know Before Choosing a Telehealth Weight Loss Platform
07/01/2026
New York City, NY, Jan. 07, 2026 (GLOBE NEWSWIRE) -- As demand for GLP-1 weight loss medications continues to rise in 2026, many consumers are actively searching for a reliable GLP-1 supplier that offers affordability, [...]
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
07/01/2026
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
07/01/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
07/01/2026
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences Halle (Saale) / Munich, Germany, January 7 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical [...]
JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
07/01/2026
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the program Supports the feasibility of intravenous and subcutaneous dosing regimens in upcoming clinical [...]
Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections
07/01/2026
Allschwil, Switzerland, January 07, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
07/01/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 7 January 2026 at 08.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
07/01/2026
Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the company’s global [...]
Best Peptides for Weight Loss 2026: Oral Wegovy Launch Expands GLP-1 Format Options as Telehealth Platforms Compare FDA-Approved vs Compounded Semaglutide Access
07/01/2026
Following Oral Wegovy Introduction, Consumer Analysis Examines Injectable vs Oral Semaglutide Pricing, Compounded Tirzepatide Access Through Direct Meds, and Three-Entity Telehealth Platform Structure HOUSTON, TX, Jan. [...]
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
07/01/2026
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for [...]
Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal
06/01/2026
CARLSBAD, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating [...]
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
06/01/2026
Conference call and webcast to be held at 8 a.m. ET on January 7, 2026 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel [...]
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK ) announced today that management will be participating in the 44 th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at [...]
Alumis Announces Proposed Public Offering of Common Stock
06/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated [...]

Pages